Gossamer Bio is trading at $11.50, up 7.98% in pre-market, with no clear company-specific overnight catalyst identified.
- Its latest prominent announcement was a September 23, 2026 submission of a New Drug Application for seralutinib, which predates this alert.
- Major U.S. indexes showed modest gains, none above 0.5%; this is not strong evidence that the broader market explains the move.
- No specific trading-volume information was provided.